Name:
Libanova, Becker and Carlos.pdf
Size:
272.9Kb
Format:
PDF
Description:
Open Access publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2012-03
Metadata
Show full item recordAbstract
The implementation of vaccination as an empiric strategy to protect against infectious diseases was introduced even before the advent of hygiene and antimicrobials in the medical practice. Nevertheless, it was not until a few decades ago that we really started understanding the underlying mechanisms of protection triggered by vaccination. Vaccines were initially based on attenuated or inactivated organisms. Subunit vaccines were then introduced as more refined formulations, exhibiting improved safety profiles. However, purified antigens tend to be poorly immunogenic and often require the use of adjuvants to achieve adequate stimulation of the immune system. Vaccination strategies, such as mucosal administration, also require potent adjuvants to improve performance. In the 1990s, immunologists found that pathogens could be sensed as 'danger signals' by receptors recognizing conserved motifs. Although our knowledge is still limited, tremendous advances were made in the understanding of host defence mechanisms regulated by these evolutionary conserved receptors, and the molecular structures which are recognized by them. This opened a new era in adjuvant development. Some of the latest players arrived to this field are the cyclic di-nucleotides, which are ubiquitous prokaryotic intracellular signalling molecules. This review is focused on their potential for the development of vaccines and immunotherapies.Citation
Cyclic di-nucleotides: new era for small molecules as adjuvants. 2012, 5 (2):168-76 Microb BiotechnolAffiliation
Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.Journal
Microbial biotechnologyPubMed ID
21958423Type
ArticleLanguage
enISSN
1751-7915ae974a485f413a2113503eed53cd6c53
10.1111/j.1751-7915.2011.00306.x
Scopus Count
The following license files are associated with this item:
Related articles
- Adjuvants: Classification, Modus Operandi, and Licensing.
- Authors: Apostólico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS
- Issue date: 2016
- Unmet needs in modern vaccinology: adjuvants to improve the immune response.
- Authors: Leroux-Roels G
- Issue date: 2010 Aug 31
- Novel Adjuvants and Immunomodulators for Veterinary Vaccines.
- Authors: Heegaard PM, Fang Y, Jungersen G
- Issue date: 2016
- A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
- Authors: Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen Å, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ
- Issue date: 2013 Nov
- Adjuvants for veterinary vaccines--types and modes of action.
- Authors: Gerdts V
- Issue date: 2015 Nov-Dec